Design, Synthesis, and Characterization of Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram-Positive Activity

被引:65
作者
Surivet, Jean-Philippe [1 ]
Zumbrunn, Cornelia [1 ]
Rueedi, Georg [1 ]
Hubschwerlen, Christian [1 ]
Bur, Daniel [1 ]
Bruyere, Thierry [1 ]
Locher, Hans [1 ]
Ritz, Daniel [1 ]
Keck, Wolfgang [1 ]
Seiler, Peter [1 ]
Kohl, Christopher [1 ]
Gauvin, Jean-Christophe [1 ]
Mirre, Azely [1 ]
Kaegi, Verena [1 ]
Dos Santos, Marina [1 ]
Gaertner, Mika [1 ]
Delers, Jonathan [1 ]
Enderlin-Paput, Michel [1 ]
Boehme, Maria [1 ]
机构
[1] Actel Pharmaceut Ltd, CH-4123 Allschwil, Switzerland
关键词
DNA GYRASE; BAD BUGS; RESISTANCE; DERIVATIVES; CHALLENGES; MUTATIONS; MECHANISM; QUINOLONE; ALDEHYDES; PROGRESS;
D O I
10.1021/jm400963y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K channel block. On the other hand, analog 49e displayed lower hERG K channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.
引用
收藏
页码:7396 / 7415
页数:20
相关论文
共 54 条
[1]   Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures [J].
AbdelMagid, AF ;
Carson, KG ;
Harris, BD ;
Maryanoff, CA ;
Shah, RD .
JOURNAL OF ORGANIC CHEMISTRY, 1996, 61 (11) :3849-3862
[2]  
Abele S., 2013, [No title captured], Patent No. [WO201338374, 201338374]
[3]   Animal model pharmacokinetics and pharmacodynamics: a critical review [J].
Andes, D ;
Craig, WA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268
[4]  
Axten J. M., 2004, [No title captured], Patent No. [WO2004002490, 2004002490]
[5]   The design of efficient and selective routes to pyridyl analogues of 2,3-dihydro-1,4-benzodioxin-6-carbaldehyde [J].
Barfoot, Christopher W. ;
Brown, Pamela ;
Dabbs, Steven ;
Davies, David T. ;
Hennessy, Alan J. ;
Miles, Timothy J. ;
Pearson, Neil D. .
TETRAHEDRON LETTERS, 2010, 51 (38) :5038-5040
[6]   A DIRECT SYNTHESIS OF OLEFINS BY REACTION OF CARBONYL-COMPOUNDS WITH LITHIO DERIVATIVES OF 2-[ALKYL-SULFONYL OR (2'-ALKENYL)-SULFONYL OR BENZYL-SULFONYL]-BENZOTHIAZOLES [J].
BAUDIN, JB ;
HAREAU, G ;
JULIA, SA ;
RUEL, O .
TETRAHEDRON LETTERS, 1991, 32 (09) :1175-1178
[7]   Type IIA topoisomerase inhibition by a new class of antibacterial agents [J].
Bax, Benjamin D. ;
Chan, Pan F. ;
Eggleston, Drake S. ;
Fosberry, Andrew ;
Gentry, Daniel R. ;
Gorrec, Fabrice ;
Giordano, Ilaria ;
Hann, Michael M. ;
Hennessy, Alan ;
Hibbs, Martin ;
Huang, Jianzhong ;
Jones, Emma ;
Jones, Jo ;
Brown, Kristin Koretke ;
Lewis, Ceri J. ;
May, Earl W. ;
Saunders, Martin R. ;
Singh, Onkar ;
Spitzfaden, Claus E. ;
Shen, Carol ;
Shillings, Anthony ;
Theobald, Andrew J. ;
Wohlkonig, Alexandre ;
Pearson, Neil D. ;
Gwynn, Michael N. .
NATURE, 2010, 466 (7309) :935-U51
[8]   Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases [J].
Black, Michael T. ;
Stachyra, Therese ;
Platel, Denis ;
Girard, Anne-Marie ;
Claudon, Monique ;
Bruneau, Jean-Michel ;
Miossec, Christine .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) :3339-3349
[9]  
Black MT, 2009, CURR OPIN INVEST DR, V10, P804
[10]  
Blakemore PR, 1998, SYNLETT, P26